These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18374677)

  • 1. Controversy over the cardiovascular effects of thiazolidinediones.
    Kapoor JR
    Am J Med; 2008 Apr; 121(4):e9. PubMed ID: 18374677
    [No Abstract]   [Full Text] [Related]  

  • 2. Faster publication isn't always better.
    Fuster V; Farkouh ME
    Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):345. PubMed ID: 17589426
    [No Abstract]   [Full Text] [Related]  

  • 3. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.
    Nagajothi N; Adigopula S; Balamuthusamy S; Velazquez-Cecena JL; Raghunathan K; Khraisat A; Singh S; Molnar J; Khosla S; Benatar D
    Am J Ther; 2008; 15(6):506-11. PubMed ID: 19127132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Avandia debate: an unhappy conclusion.
    Bloomgarden Z; Handelsman Y
    J Diabetes; 2010 Dec; 2(4):221-2. PubMed ID: 20923505
    [No Abstract]   [Full Text] [Related]  

  • 5. Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.
    Harv Heart Lett; 2007 Aug; 17(12):1-2. PubMed ID: 17717888
    [No Abstract]   [Full Text] [Related]  

  • 6. Comment: Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Musini VM; Bassett KL; Tejani AM
    Ann Pharmacother; 2009 Feb; 43(2):391-2; author reply 392-3. PubMed ID: 19193598
    [No Abstract]   [Full Text] [Related]  

  • 7. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration.
    Woodcock J; Sharfstein JM; Hamburg M
    N Engl J Med; 2010 Oct; 363(16):1489-91. PubMed ID: 20942663
    [No Abstract]   [Full Text] [Related]  

  • 8. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rosiglitazone--statistics for benefits and problems].
    Hjelmesaeth J; Røislien J
    Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2702-3. PubMed ID: 17952157
    [No Abstract]   [Full Text] [Related]  

  • 10. The rosigliazone meta-analysis: lessons for the future.
    Shuster JJ; Schatz DA
    Diabetes Care; 2008 Mar; 31(3):e10. PubMed ID: 18308673
    [No Abstract]   [Full Text] [Related]  

  • 11. [Glitazone - mailing no 3. In response to DMW 49/2007].
    Gundel UF
    Dtsch Med Wochenschr; 2008 Feb; 133(6):261-2; author reply 262-3. PubMed ID: 18236354
    [No Abstract]   [Full Text] [Related]  

  • 12. [Insulin resistance increases risk of infarct. Glitazone now approved also for monotherapy].
    MMW Fortschr Med; 2003 Sep; 145(38):61. PubMed ID: 14603688
    [No Abstract]   [Full Text] [Related]  

  • 13. Thiazolidinediones and clinical diabetes management: new challenges for the fall of 2007.
    Boyle P
    South Med J; 2007 Nov; 100(11):1063-4. PubMed ID: 17984728
    [No Abstract]   [Full Text] [Related]  

  • 14. [Glitazone - mailing no 1. In response to DMW 49/2007].
    Traut V
    Dtsch Med Wochenschr; 2008 Feb; 133(6):261; author reply 262-3. PubMed ID: 18236356
    [No Abstract]   [Full Text] [Related]  

  • 15. Analytical issues regarding rosiglitazone meta-analysis.
    Claggett B; Wei LJ
    Arch Intern Med; 2011 Jan; 171(2):179-80; author reply 180. PubMed ID: 21263111
    [No Abstract]   [Full Text] [Related]  

  • 16. [From cardiovascular risk to chronic heart failure].
    Ertl G
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():17. PubMed ID: 14694837
    [No Abstract]   [Full Text] [Related]  

  • 17. Thiazolidinediones and cardiovascular risk: will the evidence so far available modify treatment strategies for type 2 diabetes?
    Vaccaro O; Riccardi G
    Nutr Metab Cardiovasc Dis; 2008 Feb; 18(2):85-7. PubMed ID: 18280715
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular risk and cardiometabolic protection: role of glitazones.
    Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
    J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Avandia debacle: methodology and practical importance of the findings.
    Meneghini LF; Florez H; Tamariz L
    South Med J; 2007 Nov; 100(11):1062-3. PubMed ID: 17984727
    [No Abstract]   [Full Text] [Related]  

  • 20. [Glitazones critically evaluated].
    Schernthaner G
    Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.